Research & Innovation

History of Ibogain in USA
 

Background and History of Ibogaine
 

Ibogaine has demonstrated promise for Opioid and substance use disorders (SUDs), psychotherapy, and personal spiritual growth.  NYC as a birth of Manhattan Project, since 1986, Howard Lotsof’s patent initiation for OUD/SUD/AUD/ and others, many ibogaine treatments are conducted “underground” subcultures in unregulated regions and may after 45 years of NYS legislation for Ibogaine, KRFI is entering into a FDA Investigative New Drug with treatments for poly opioid protocols to ensure the safety of the participant. This study arose to fill the Poly drug opioid endemic and bring evidence base collective data on the potential of ibogaine as a treatment option with the global scientific communities and for health equity and mental health treatment policy.
 

In the History of New York State Funding and Research are (1) synthetic ibogaine and OUD products MC 18, a non psychedelic synthetic ibogaine has been diverse for the Albany Medical and Mindmed had received 6 Mn conducted its phase 1 studies in Brazil in 2000;
(2) IboOxy currently under clinical development by Gilgamesh and Abbie is a non psychedelic synthetic ibogaine has received 14 Mn from NIDA in 2024;  and,
(3)  Atai Life Sciences currently under MHRA studies in UK has received the 14Mn for OUD synthetic product from NIDA in 2025.